Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a studyHIV에 감염되지 않은 건강한 성인을 대상으로 한 두 가지 이종 HIV 백신 요법의 안전성 및 면역원성(TRAVERSE): 무작위 배정, 병렬 그룹, 위약 대조, 이중 맹검, 1/2a상 연구Articles Published on 2020-09-302022-09-06 Journal: The Lancet. HIV [Category] Communicable Disease, [키워드] 95% CI Ad26 Adenovirus Administered advancement adverse event adverse events aligned All participant All participants Analysis Antigen antigens applied assigned binding antibodies binding antibody blood sample breadth CD4+ T-cell clade collected computer-generated Defense Deltoid muscle Department diagnosed dose double-blind Efficacy elicit Eligible participants ELISpot responses enrolled finding first vaccination foundation funding group groups healthy Heterologous HIV HIV infection HIV vaccine HIV-1 infection HIV-uninfected IFNγ ELISPOT response IFNγ ELISPOT responses IgG immune response immune responses Immunity immunogenicity injection Intramuscular injection investigator investigators Jackson janssen Laboratory Local magnitude median medical history Medicine Melinda Gate Melinda Gates Military Medicine mononuclear cell mononuclear cells opinion Other parallel-group participant PBMC PBMCs per protocol per-protocol Peripheral blood Peripheral blood mononuclear cells Physical examination Placebo placebo group placebo-controlled placebos prevention randomisation randomised Randomly randomly permuted block randomly permuted blocks regimen regimens Registered repeated risk Safe Safety second vaccination Sponsor stratified subgroups systemic reactogenicity T-cell Response tested tetravalent the placebo group titre titres Tolerability treatment allocation Trial trivalent USA vaccination vaccination schedule Vaccinations Vaccine vaccine group vectored vaccine vital sign was done with HIV [DOI] 10.1016/S2352-3018(20)30229-0 PMC 바로가기 [Article Type] Articles
Positively Charged Electroceutical Spun Chitosan Nanofibers Can Protect Health Care Providers From COVID-19 Infection: An OpinionBioengineering and Biotechnology Published on 2020-08-182022-10-31 Journal: Frontiers in Bioengineering and Biotechnology [Category] COVID-19, [키워드] Can chitosan COVID - 19 COVID-19 electrospinning health care provider (HCP) nanofi bers Nanofiber opinion SARS - CoV-2 textile–clothing industry [DOI] 10.3389/fbioe.2020.00885 PMC 바로가기 [Article Type] Bioengineering and Biotechnology
Indirect implications of COVID-19 prevention strategies on non-communicable diseases An Opinion Paper of the European Society of Hypertension Working Group on Hypertension and Cardiovascular Risk Assessment in Subjects Living in or Emigrating from Low Resource SettingsOpinion Published on 2020-08-142022-10-28 Journal: BMC Medicine [Category] COVID-19, MERS, [키워드] affected assessment Cancer cardiovascular cardiovascular disease Care China coronavirus country COVID-19 diabetes Effect effective European globe group health system healthcare personnel hypertension implication indirect effect Infection prevention intensive care unit Isolation Non-communicable disease non-communicable diseases opinion outbreak paper Patient pulmonary complications reported Respiratory disease risk SARS-CoV-2 setting social distancing Society Treatment working [DOI] 10.1186/s12916-020-01723-6 PMC 바로가기 [Article Type] Opinion
Internet Public Opinion Evolution in the COVID-19 Event and Coping StrategiesOriginal Research Published on 2020-08-122022-10-31 Journal: Disaster Medicine and Public Health Preparedness [Category] COVID-19, MERS, SARS, [키워드] Analysis Baidu Bar carried China Chinese Combination Community coping coronavirus disease Correlation analysis COVID-19 diffusion emotional Epidemic Factor Government Health Infection information Internet Internet public opinion latent Dirichlet allocation (LDA) majority management Measures media opinion outbreak performed positive Public public health emergency sentiment analysis shown spread of COVID-19 Strategy Symptoms Transmission was performed [DOI] 10.1017/dmp.2020.299 PMC 바로가기 [Article Type] Original Research
muLTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19-Experimental drugs and mechanisms (TACTIC-E): A structured summary of a study protocol for a randomized controlled trial코비드-19-실험 약물 및 기전(TACTIC-E)으로 입원한 ICu 전 환자에 대한 다중 암 치료 연구: 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-312022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] able to swallow adaptive Adaptive trial added Admission age Ambrisentan Analysis analysis approved Arm ARMS balloon pump balloon pump) baseline benefit Biomarker blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not cardiac cardiovascular complications cells clearance clinical endpoint Clinical endpoints clinical picture clinically Combination comparator comparison Complete Composite Course COVID-19 COVID-19 infection creatinine creatinine clearance CRP Dapagliflozin Data analysis Day death defined demonstrated determine diabetes Diagnosis discretion disease dissemination drug drugs ECMO EDP1815 Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT Evidence evidence of exclusion criteria Experimental drugs failure feature fixed foundation Gault Gender group hypertension immunomodulation immunomodulatory incidence include Inclusion independent independent data monitoring committee Inotropes Intervention Invasive mechanical ventilation investigator Laboratory late stage male mechanism membrane neutrophil Neutrophils NHS number objective Occurrence on admission once daily Open-label open-label trial opinion option Organ failure organ support Other outcome Oxygenation pandemic Parallel Arm participant Patient patients with COVID-19 performed phase platform Platform trial positive positive COVID-19 predicted Primary outcome principal investigator progression protocol Radiographic radiological randomisation randomised Randomized controlled trial recruited reduce Registered related disease renal renal failure risk Sample size severity Standard of care status stratified Study protocol subject Support tablets the patient therapy Treatment treatment arm Trial Trial registration triggered Trust university website [DOI] 10.1186/s13063-020-04618-2 PMC 바로가기 [Article Type] Letter
Repurposed immunomodulatory drugs for Covid-19 in pre-ICu patients – mulTi-Arm Therapeutic study in pre-ICu patients admitted with Covid-19 – Repurposed Drugs (TACTIC-R): A structured summary of a study protocol for a randomised controlled trialICu 전 환자의 Covid-19에 대한 용도 변경 면역조절 약물 - Covid-19로 입원한 ICu 전 환자에 대한 다중 암 치료 연구 – 용도 변경 약물(TACTIC-R): 무작위 대조 시험을 위한 연구 프로토콜의 구조화된 요약Letter Published on 2020-07-082022-08-13 Journal: Trials [Category] SARS, 임상, [키워드] Administered Admission age Analysis analysis Arm ARMS balloon pump balloon pump) Baricitinib baseline blinded Blinding calculated Cambridge Cambridge University Hospitals NHS Foundation Trust can not candidate cardiac clearance clinical picture college comparator comparison Complete COVID-19 infection creatinine creatinine clearance CRP Data analysis Data monitoring committee Day death defined determine diabetes Diagnosis discharge disease dissemination dose drug Drug evaluation Efficacy element enrolled envelope EU Clinical Trial EU Clinical Trials EudraCT event exclusion criteria feature fixed foundation Gault Gender hypertension IDMC immunomodulatory immunomodulatory drug immunomodulatory drugs Immunomodulatory therapies immunomodulatory therapy incidence include Inclusion independent data monitoring committee initial Inotropes interim analysis Intervention intravenously Invasive mechanical ventilation investigator ISRCTN late stage Local male membrane neutrophil Neutrophils NHS number objective on admission once daily Open-label open-label trial opinion Organ failure organ support outcome Oxygenation participant Patient phase Platform trial positive positive COVID-19 predicted Primary outcome progression Prophylaxis protocol Radiographic radiological randomisation randomised randomised controlled trial Ravulizumab recruited recruitment reduce reduced regimen Registered related disease renal renal failure Repurposed drugs risk Sample size scalability selected severity SOC stage 2 Standard of care status stratified Study protocol subject Support Toxicity treatment arm Trial Trial registration triggered Trust university university hospital Venous Thromboembolism website [DOI] 10.1186/s13063-020-04535-4 PMC 바로가기 [Article Type] Letter
How to strengthen a health research system: WHO’s review, whose literature and who is providing leadership?Opinion Published on 2020-06-232022-10-31 Journal: Health Research Policy and Systems [Category] Coronavirus, SARS, [키워드] addressed Analysis approach Biomedical research Capacity-building comprehensive strategy COVID-19 crisis effective England English Europe Evidence evidence-based practice FIVE function Health Health ministries Health research systems Health services research health systems helping identify Impact include Ireland Local National office opinion Policy Policy-making Priority-setting producing provide Regional Research research finding Research utilisation Sustainable Development Goals translational medical research West WHO WHO’ [DOI] 10.1186/s12961-020-00581-1 PMC 바로가기 [Article Type] Opinion
Novel coronavirus and regular physical activity involvement: OpinionShort Report Published on 2020-05-212022-10-28 Journal: African Journal of Primary Health Care & Family Me [Category] COVID-19, MERS, SARS, [키워드] alcohol Anxiety breathing exercises complementary condition coronavirus country Depression drug Evidence immune system include infections medical treatment nCOVID-19 novel Novel coronavirus opinion physical activity Physical exercise Prevent public health respiratory difficulties smoking SSA sub-Saharan Africa treat Treatment Vaccine virus Well-being while [DOI] 10.4102/phcfm.v12i1.2453 PMC 바로가기 [Article Type] Short Report